Drug Name: Lunsumio
Active Ingredient: mosunetuzumab-axgb
Indications: To treat adults with relapsed or refractory follicular lymphoma, a type of non-Hodgkin lymphoma
Approval Date: 12/22/2022
Company: Genentech, Inc Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761263s000lbl.pdf